April 2026
M	T	W	T	F	S	S
	1	2	3	4	5
6	7	8	9	10	11	12
13	14	15	16	17	18	19
20	21	22	23	24	25	26
27	28	29	30

Bastu Odoka: The Laboratory’s Role in Preventing RhD Disease

Bastu Odoka/LinkedIn

Mar 10, 2026, 12:23

Bastu Odoka: The Laboratory’s Role in Preventing RhD Disease

Bastu Odoka, Transfusion Scientist at Effia-Nkwanta Regional Hospital, shared a post on LinkedIn:

”The Laboratory’s Role in Preventing RhD Disease

When discussing prevention of RhD disease (HDFN), attention is often placed on:

Anti-D injections
Obstetric care

Clinical decision-making

But one critical part of the prevention chain is sometimes overlooked:
The laboratory.

In reality, the fight against RhD disease starts in the laboratory.

Accurate blood grouping is the first defence
ABO and RhD grouping may appear routine, but it is one of the most important steps in preventing sensitisation.

Laboratories should ensure:

Proper RhD typing
Weak D testing on samples initially typed RhD-negative, according to laboratory policy and testing algorithms

This helps prevent misclassification of RhD status.

Incorrect RhD typing can have serious consequences.

Typing an RhD-positive mother as RhD-negative may lead to unnecessary use of Anti-D, placing pressure on an already limited resource.
Typing an RhD-negative mother as RhD-positive may result in missed prophylaxis, increasing the risk of sensitisation and future HDFN and unnecessary financial burden on the mother.

Antibody screening helps identify sensitisation early

Routine antibody screening (Indirect Antiglobulin Test) plays a critical role in:

Detecting clinically significant antibodies
Identifying mothers who are already sensitised
Guiding appropriate clinical management

Without antibody screening, sensitisation may remain undetected until complications occur.

Quantifying fetomaternal haemorrhage

Tests such as the Kleihauer-Betke (KB) test help estimate the volume of fetomaternal haemorrhage (FMH) by detecting fetal red cells in maternal circulation.

This information can guide the appropriate Anti-D dose, particularly when significant fetomaternal haemorrhage is suspected.

Safe transfusion also matters
Preventing RhD sensitisation is not only an obstetric issue.

Laboratories must ensure:

Accurate typing of donor blood
Proper compatibility testing
Avoidance of RhD-positive transfusion to RhD-negative women of childbearing age whenever possible

Transfusion-related sensitisation can also lead to future HDFN.

In Ghana and similar resource-limited settings, routine antibody screening and fetomaternal haemorrhage testing are not consistently performed.

This is where laboratory professionals must take leadership.

Strengthening laboratory practices can significantly improve prevention of RhD disease.

Key message
Preventing RhD disease is a team effort.

The chain begins with: